Literature DB >> 17334266

Neuropathologic heterogeneity in HDDD1: a familial frontotemporal lobar degeneration with ubiquitin-positive inclusions and progranulin mutation.

Maria I Behrens1, Odity Mukherjee, Pang-hsien Tu, Rajka M Liscic, Lea Tenenholz Grinberg, Deborah Carter, Katherine Paulsmeyer, Lisa Taylor-Reinwald, Michael Gitcho, Joanne B Norton, Sumi Chakraverty, Alison M Goate, John C Morris, Nigel J Cairns.   

Abstract

Hereditary dysphasic disinhibition dementia (HDDD) describes a familial disorder characterized by personality changes, and language and memory deficits. The neuropathology includes frontotemporal lobar atrophy, neuronal loss and gliosis and, in most cases, abundant Abeta plaques and neurofibrillary tangles (NFTs). A Pick/Alzheimer's spectrum was proposed for the original family (HDDD1). Here we report the clinicopathologic case of an HDDD1 individual using modern immunohistochemical methods, contemporary neuropathologic diagnostic criteria to distinguish different frontotemporal lobar degenerations (FTLDs), and progranulin (PRGN) mutation analysis. Clinical onset was at age 62 years with personality changes and disinhibition, followed by nonfluent dysphasia, and memory loss that progressed to muteness and total dependence with death at age 84 years. There was severe generalized brain atrophy (weight=570 g). Histopathology showed superficial microvacuolation, marked neuronal loss, gliosis, and ubiquitin-positive, tau-negative cytoplasmic and intranuclear neuronal inclusions in frontal, temporal, and parietal cortices. There were also frequent neuritic plaques and NFTs in parietal and occipital cortices. The case met neuropathologic criteria for both FTLD with ubiquitin-positive, tau-negative inclusions (FTLD-U), and Alzheimer disease (Braak NFT stage V). We discovered a novel pathogenic PGRN mutation c.5913 A>G (IVS6-2 A>G) segregating with FTLD-U in this kindred. In conclusion, HDDD1 is an FTLD-U caused by a PGRN mutation and is neuropathologically heterogeneous with Alzheimer disease as a common comorbidity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17334266     DOI: 10.1097/WAD.0b013e31803083f2

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  23 in total

1.  Core features of frontotemporal dementia recapitulated in progranulin knockout mice.

Authors:  N Ghoshal; J T Dearborn; D F Wozniak; N J Cairns
Journal:  Neurobiol Dis       Date:  2011-09-10       Impact factor: 5.996

Review 2.  Update on recent molecular and genetic advances in frontotemporal lobar degeneration.

Authors:  Eileen H Bigio
Journal:  J Neuropathol Exp Neurol       Date:  2008-07       Impact factor: 3.685

3.  Frequency of progranulin mutations in a German cohort of 79 frontotemporal dementia patients.

Authors:  Johannes Carolus Magnus Schlachetzki; Klaus Schmidtke; Jan Beckervordersandforth; Wiktor Borozdin; Christian Wilhelm; Michael Hüll; Jürgen Kohlhase
Journal:  J Neurol       Date:  2009-07-19       Impact factor: 4.849

4.  Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels.

Authors:  Carlos Cruchaga; Caroline Graff; Huei-Hsin Chiang; Jun Wang; Anthony L Hinrichs; Noah Spiegel; Sarah Bertelsen; Kevin Mayo; Joanne B Norton; John C Morris; Alison Goate
Journal:  Arch Neurol       Date:  2011-01-10

5.  Laminar distribution of the pathological changes in sporadic frontotemporal lobar degeneration with transactive response (TAR) DNA-binding protein of 43 kDa (TDP-43) proteinopathy: a quantitative study using polynomial curve fitting.

Authors:  R A Armstrong; R L Hamilton; I R A Mackenzie; J Hedreen; N J Cairns
Journal:  Neuropathol Appl Neurobiol       Date:  2013-06       Impact factor: 8.090

6.  Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration.

Authors:  Nigel J Cairns; Eileen H Bigio; Ian R A Mackenzie; Manuela Neumann; Virginia M-Y Lee; Kimmo J Hatanpaa; Charles L White; Julie A Schneider; Lea Tenenholz Grinberg; Glenda Halliday; Charles Duyckaerts; James S Lowe; Ida E Holm; Markus Tolnay; Koichi Okamoto; Hideaki Yokoo; Shigeo Murayama; John Woulfe; David G Munoz; Dennis W Dickson; Paul G Ince; John Q Trojanowski; David M A Mann
Journal:  Acta Neuropathol       Date:  2007-06-20       Impact factor: 17.088

7.  Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report.

Authors:  Nigel J Cairns; Milos D Ikonomovic; Tammie Benzinger; Martha Storandt; Anne M Fagan; Aarti R Shah; Lisa Taylor Reinwald; Deborah Carter; Angela Felton; David M Holtzman; Mark A Mintun; William E Klunk; John C Morris
Journal:  Arch Neurol       Date:  2009-12

8.  Neuropathological heterogeneity in frontotemporal lobar degeneration with TDP-43 proteinopathy: a quantitative study of 94 cases using principal components analysis.

Authors:  Richard A Armstrong; William Ellis; Ronald L Hamilton; Ian R A Mackenzie; John Hedreen; Marla Gearing; Thomas Montine; Jean-Paul Vonsattel; Elizabeth Head; Andrew P Lieberman; Nigel J Cairns
Journal:  J Neural Transm (Vienna)       Date:  2009-12-10       Impact factor: 3.575

Review 9.  A common biological mechanism in cancer and Alzheimer's disease?

Authors:  M I Behrens; C Lendon; C M Roe
Journal:  Curr Alzheimer Res       Date:  2009-06       Impact factor: 3.498

10.  TARDBP 3'-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy.

Authors:  Michael A Gitcho; Eileen H Bigio; Manjari Mishra; Nancy Johnson; Sandra Weintraub; Marsel Mesulam; Rosa Rademakers; Sumi Chakraverty; Carlos Cruchaga; John C Morris; Alison M Goate; Nigel J Cairns
Journal:  Acta Neuropathol       Date:  2009-07-18       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.